Nemaura Medical Inc. (NMRD)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
May 26, 2026, 9:30 AM EST
Nemaura Medical Revenue
In the fiscal year ending March 31, 2023, Nemaura Medical had annual revenue of $77.04K, down -84.71%.
Revenue
77.04K
Revenue Growth
-84.71%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
36
Market Cap
4.04K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2023 | 77.04K | -426.86K | -84.71% |
| Mar 31, 2022 | 503.91K | - | - |
| Mar 31, 2021 | - | - | - |
| Mar 31, 2020 | - | - | - |
| Mar 31, 2019 | - | - | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Acutus Medical | 20.16M |
| Telesis Bio | 17.03M |
| Urologix | 12.00M |
| Viveve Medical | 6.83M |
| Caliber Imaging & Diagnostics | 3.14M |
| SurgLine International | 113.62K |
| Forza Innovations | 93.99K |
Nemaura Medical News
- 2 years ago - Twelve option delistings on June 24th - TheFly
- 2 years ago - Nemaura Medical decides to accept Nasdaq determination to delist - TheFly
- 2 years ago - Important Update on Listing Status and Strategic Direction - GlobeNewsWire
- 2 years ago - Nemaura Medical receives positive Nasdaq listing decision - TheFly
- 2 years ago - Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision - GlobeNewsWire
- 2 years ago - Nemaura Medical secures $10M non-dilutive credit facility - TheFly
- 2 years ago - Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth - GlobeNewsWire
- 2 years ago - Nemaura Medical rating moved to under review at H.C. Wainwright - TheFly